English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Over the last two decades, and in particular since the completion of the Human Genome Project, medicine has been slowly but persistently moving towards personalized medicine – medical treatments tailored for the individual patient based on genetic and genomic information derived from patients' biological samples (blood samples and biopsied tissues). A major aim of this approach is to prescribe the right drug at the right dosage and right time for each patient. Another key aim of precision medicine is allowing earlier disease diagnosis, so that patients are treated with preventive therapeutics before the disease has caused irreparable damage. However, personalized medicine research is often hampered by high costs and lack of high-quality biological samples. Human lymphoblastoid cell lines (LCLs) are an affordable research tool that can be of high value for disease and drug response biomarker discovery in the context of personalized medicine exploration and can be obtained from many human biobanks.

Human lymphoblastoid cell lines: a valuable tool for personalized medicine research